Chemagis Ltd.

Wavelength Enterprises Ltd

Perrigo Api Ltd.

Able Tx Ltd

Itai Adin

Joseph Kaspi

Yevgeny Rozenblat

Oded Arad

Vladimir Naddaka

Ori Lerman

Ana Fernandez Casares

Shady Saeed

Sonia Krivonos

Mohammed Alnabari

Eyal Klopfer

Nir Betser

Gloria Ten Figas

Revital Ben-Daniel

Alex Weisman

Yana Sery

Alexander Weisman

Ana Fernadez Casares

Yuri Futerman

Chaim Ashkenazi

Carmen Iustain

Keren Hadar

Provided are ibrutinib polymorphs, e.g., crystalline ibrutinib Forms III, IV, V, VI, VII, VIII and Form IX and processes for producing these crystalline forms, stable amorphous ibrutinib and processes for preparing stable amorphous ibrutinib, pharmaceutical compositions comprising these forms and methods of using these crystalline and amorphous forms.

Ibrutinib solid forms and production process therefor

Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions.

Crystalline forms of temozolomide

An amorphous form of montelukast sodium and a montelukast sodium lactose co-precipitate, processes for producing same, pharmaceutical compositions containing same and methods of treatment utilizing same are disclosed.

Stable amorphous forms of montelukast sodium

The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.

Crystalline forms of halobetasol propionate

Growing community of inventors

Beer Sheva, Israel

Itai Adin